MobiHealth News December 6, 2023
The companies will leverage Absci’s AI-enabled Integrated Drug Creation platform and the pharma giant’s oncology research and development expertise.
Absci, a startup focused on developing generative AI antibody discovery technology, announced a potential $247 million partnership with pharma giant AstraZeneca to focus on expediting the discovery of novel cancer treatments with the help of genAI technology.
The project will leverage Absci’s Integrated Drug Creation platform – which combines scalable wet lab technologies with AI, and facilitates optimization of multiple drug features pivotal for therapeutic advantages – and AstraZeneca’s oncology research and development knowledge.
The collaboration aims to utilize Absci’s de novo “zero-shot” AI models that result in new, improved antibody therapies against cancer.
The “zero-shot” generative AI technique developed by...
Today's Sponsors
Today's Sponsor